Sabrina Serani

Patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer treated with nadofaragene firadenovec experienced lasting responses to the therapy for up to 3 years.

The FDA approved tovorafenib for certain patients with relapsed or refractory pediatric low-grade glioma.

Tumor-treating fields significantly improved the time to intracranial progression in patients from the phase 3 METIS trial with brain metastases from non-small cell lung cancer.

The American Society of Clinical Oncology updated its vaccine guidelines for patients with cancer — a population that may have a heightened infection risk.

Based on results from a post hoc analysis, researchers found that lurbinectedin was more effective and less toxic than topotecan for the treatment of small cell lung cancer.

Detecting minimal residual disease with ctDNA in patients with stage II/III colorectal cancer may strongly predict disease recurrence and the potential benefit from adjuvant chemotherapy.